The EPIPEN Act would require health insurance plans to limit patient costs for epinephrine auto-injectors to no more than $60 per package of two injectors, with no deductibles applied to these lifesaving medications. The legislation applies to group health plans offered by employers and to both group and individual health insurance policies sold on the market, affecting millions of Americans with severe allergies who depend on epinephrine injectors. Any out-of-pocket costs paid for epinephrine injectors would count toward patients' annual deductibles and out-of-pocket maximums, providing some relief from overall health care expenses. The bill would take effect on January 1, 2025, and does not require coverage for injectors obtained from out-of-network providers, which could potentially have higher cost-sharing. This legislation addresses concerns about the high price of epinephrine auto-injectors, which have increased significantly in recent years and can be unaffordable for patients despite being essential emergency medications.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.